Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pulmonx (LUNG) EBT (2019 - 2025)

Pulmonx has reported EBT over the past 7 years, most recently at -$13.8 million for Q3 2025.

  • Quarterly EBT rose 0.88% to -$13.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$56.3 million through Sep 2025, changed 0.22% year-over-year, with the annual reading at -$55.9 million for FY2024, 7.26% up from the prior year.
  • EBT was -$13.8 million for Q3 2025 at Pulmonx, up from -$15.0 million in the prior quarter.
  • Over five years, EBT peaked at -$10.1 million in Q3 2021 and troughed at -$16.1 million in Q2 2023.
  • The 5-year median for EBT is -$14.0 million (2022), against an average of -$14.0 million.
  • Year-over-year, EBT crashed 165.99% in 2021 and then rose 13.81% in 2024.
  • A 5-year view of EBT shows it stood at -$12.9 million in 2021, then dropped by 9.2% to -$14.0 million in 2022, then rose by 2.83% to -$13.6 million in 2023, then grew by 3.69% to -$13.1 million in 2024, then decreased by 5.27% to -$13.8 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's EBT are -$13.8 million (Q3 2025), -$15.0 million (Q2 2025), and -$14.3 million (Q1 2025).